Ergothioneine vs PNC-27
A side-by-side research comparison of Ergothioneine and PNC-27 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Ergothioneine | PNC-27 |
|---|---|---|
| Full name | L-Ergothioneine | PNC-27 (p53-Derived Anticancer Peptide) |
| Category | Detox & Antioxidant | Detox & Antioxidant |
| Status | OTC supplement | Research compound (preclinical) |
| Mechanism | Accumulates via the OCTN1 transporter in mitochondria and other high-stress cellular compartments, where it scavenges reactive oxygen species, chelates metals, protects DNA and mitochondria, and preserves other antioxidants. | Contains a p53 domain fused to a membrane-penetrating sequence. It is proposed to bind HDM-2 that is preferentially expressed on cancer cell membranes, forming pores that cause selective necrosis of cancer cells while reportedly sparing normal cells in studies. |
| Molecular weight | 229.30 Da | ~3.2 kDa |
| Half-life | Very long (weeks; retained in tissue) | Short (peptide) |
| Bioavailability | Good oral via OCTN1 transporter | Injection (research) |
| Typical dose | 5-25 mg per day | Not established for humans |
| Frequency | Once daily | Research only |
| Route | Oral capsule | Injection (research) |
Ergothioneine reported benefits
- Potent cellular and mitochondrial antioxidant
- Long tissue retention
- DNA and lipid protection
- Neuroprotective potential
- Associated with lower age-related disease risk
- Anti-inflammatory
PNC-27 reported benefits
- Selective cancer-cell targeting (preclinical)
- p53/HDM-2 mechanism of interest
- Reported sparing of normal cells (studies)
Related comparisons
Research and educational reference only. Not medical advice.